Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers. 2008

Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
Institute of Pharmacology, Center of Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria.

Duramycin (Moli1901) is being developed for the treatment of reduced mucociliary clearance in cystic fibrosis. This study was conducted to estimate lung residence time and systemic exposure and to assess whether duramycin causes an inflammatory response. Six volunteers were administered a single dose (7.5 mg) of nebulized duramycin and underwent bronchoscopies to obtain a composite data set for pharmacokinetic analysis; duramycin was measured in the cellular fraction of bronchoalveolar lavage fluid (BALF) (mainly alveolar macrophages) and brush biopsies (bronchial epithelial cells). The estimated t(1/2) of duramycin was approximately 5 days in brush biopsies and 25 to 91 days in BALF cells. Levels of duramycin in BALF (C (max) 800 ng/mg) exceeded those in brush biopsies by approximately 20-fold. Duramycin was absent from plasma and did not cause any detectable inflammatory response in pulmonary tissue as judged from the BALF profile of 14 relevant cytokines. Our data suggest that duramycin qualifies for intrapulmonary administration in cystic fibrosis (CF) patients.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D009330 Nebulizers and Vaporizers Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments. Atomizers,Inhalation Devices,Inhalators,Inhalers,Vaporizers,Nebulizers,Vaporizers and Nebulizers,Atomizer,Device, Inhalation,Devices, Inhalation,Inhalation Device,Inhalator,Inhaler,Nebulizer,Vaporizer
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D001999 Bronchoscopy Endoscopic examination, therapy or surgery of the bronchi. Bronchoscopic Surgical Procedures,Surgical Procedures, Bronchoscopic,Bronchoscopic Surgery,Surgery, Bronchoscopic,Bronchoscopic Surgeries,Bronchoscopic Surgical Procedure,Bronchoscopies,Surgeries, Bronchoscopic,Surgical Procedure, Bronchoscopic
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
April 2023, Journal of aerosol medicine and pulmonary drug delivery,
Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
October 2004, Biopharmaceutics & drug disposition,
Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
February 2019, Clinical therapeutics,
Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
January 2004, Journal of clinical pharmacology,
Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
September 1994, Journal of clinical pharmacology,
Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
October 1999, Biopharmaceutics & drug disposition,
Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
April 2007, British journal of clinical pharmacology,
Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
April 2004, Transfusion medicine (Oxford, England),
Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
May 2024, Clinical drug investigation,
Ilka Steiner, and Peter Errhalt, and Klaus Kubesch, and Marianne Hubner, and Marion Holy, and Martin Bauer, and Markus Müller, and Sabine Hinterberger, and Rudolf Widmann, and Daniel Mascher, and Michael Freissmuth, and Meinhard Kneussl
October 1989, Investigative radiology,
Copied contents to your clipboard!